Phibro Animal Health Corp (PAHC)
12.44
-0.12
(-0.96%)
USD |
NASDAQ |
Apr 25, 16:00
12.45
+0.01
(+0.08%)
After-Hours: 20:00
Phibro Animal Health SG&A Expense (Quarterly): 62.92M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 62.92M |
September 30, 2023 | 68.45M |
June 30, 2023 | 52.90M |
March 31, 2023 | 56.99M |
December 31, 2022 | 61.54M |
September 30, 2022 | 54.96M |
June 30, 2022 | 55.54M |
March 31, 2022 | 52.43M |
December 31, 2021 | 48.38M |
September 30, 2021 | 50.07M |
June 30, 2021 | 50.67M |
March 31, 2021 | 49.03M |
December 31, 2020 | 48.38M |
September 30, 2020 | 48.43M |
June 30, 2020 | 42.44M |
March 31, 2020 | 48.23M |
December 31, 2019 | 49.50M |
September 30, 2019 | 47.52M |
June 30, 2019 | 53.20M |
March 31, 2019 | 42.30M |
December 31, 2018 | 42.94M |
September 30, 2018 | 42.95M |
June 30, 2018 | 41.40M |
Date | Value |
---|---|
March 31, 2018 | 42.58M |
December 31, 2017 | 42.98M |
September 30, 2017 | 41.00M |
June 30, 2017 | 39.61M |
March 31, 2017 | 30.65M |
December 31, 2016 | 40.87M |
September 30, 2016 | 39.19M |
June 30, 2016 | 39.48M |
March 31, 2016 | 37.62M |
December 31, 2015 | 38.84M |
September 30, 2015 | 37.35M |
June 30, 2015 | 36.79M |
March 31, 2015 | 37.30M |
December 31, 2014 | 36.30M |
September 30, 2014 | 35.22M |
June 30, 2014 | 37.85M |
March 31, 2014 | 35.52M |
December 31, 2013 | 34.14M |
September 30, 2013 | 33.12M |
June 30, 2013 | 33.25M |
March 31, 2013 | 31.30M |
December 31, 2012 | 29.03M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
42.44M
Minimum
Jun 2020
68.45M
Maximum
Sep 2023
52.71M
Average
50.67M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Stryker Corp | 1.941B |
Boston Scientific Corp | 1.379B |
Steris PLC | 360.52M |
Envista Holdings Corp | 260.20M |
Perspective Therapeutics Inc | 1.694M |